Online inquiry

IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6812MR)

This product GTTS-WQ6812MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets STEAP1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012449.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26872
UniProt ID Q9UHE8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6812MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ981MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15801MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13174MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ8723MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ1287MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ10261MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ15545MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ10215MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW